Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes

William Tobin, J. A. Kinsella, G. F. Kavanagh, J. S. O'Donnell, R. T. McGrath, S. Tierney, B. Egan, T. M. Feeley, T. Coughlan, D. R. Collins, D. O'Neill, S. J.X. Murphy, S. J. Lim, R. P. Murphy, D. J.H. McCabe

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction Von Willebrand factor propeptide (VWF:Ag II) is proposed to be a more sensitive marker of acute endothelial activation than von Willebrand factor antigen (VWF:Ag). Simultaneous data on VWF:Ag and VWF:Ag II profiles are very limited following TIA and ischaemic stroke. Methods In this prospective, observational, case-control study, plasma VWF:Ag and VWF:Ag II levels were quantified in 164 patients ≤ 4 weeks of TIA or ischaemic stroke (baseline), and then ≥ 14 days (14d) and ≥ 90 days (90d) later, and compared with those from 27 healthy controls. TIA and stroke subtyping was performed according to the TOAST classification. The relationship between VWF:Ag and VWF:Ag II levels and platelet activation status was assessed. Results ‘Unadjusted’ VWF:Ag and VWF:Ag II levels were higher in patients at baseline, 14d and 90d than in controls (p ≤ 0.03). VWF:Ag levels remained higher in patients than controls at baseline (p ≤ 0.03), but not at 14d or 90d after controlling for differences in age or hypertension, and were higher in patients at baseline and 90d after controlling for smoking status (p ≤ 0.04). ‘Adjusted’ VWF:Ag II levels were not higher in patients than controls after controlling for age, hypertension or smoking (p ≥ 0.1). Patients with symptomatic carotid stenosis (N = 46) had higher VWF:Ag and VWF:Ag II levels than controls at all time-points (p ≤ 0.002). There was no significant correlation between platelet activation status and VWF:Ag or VWF:Ag II levels. Conclusions VWF:Ag and VWF:Ag II levels are increased in an overall TIA and ischaemic stroke population, especially in patients with recently symptomatic carotid stenosis. VWF:Ag II was not superior to VWF:Ag at detecting acute endothelial activation in this cohort and might reflect timing of blood sampling in our study.

Original languageEnglish (US)
Pages (from-to)404-410
Number of pages7
JournalJournal of the Neurological Sciences
Volume375
DOIs
StatePublished - Apr 15 2017

Fingerprint

von Willebrand Factor
Stroke
Population
Von Willebrand antigen
Carotid Stenosis
Platelet Activation
Smoking
Hypertension

Keywords

  • Case-control
  • Stroke
  • TIA
  • Von Willebrand factor
  • Von Willebrand factor propeptide

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes. / Tobin, William; Kinsella, J. A.; Kavanagh, G. F.; O'Donnell, J. S.; McGrath, R. T.; Tierney, S.; Egan, B.; Feeley, T. M.; Coughlan, T.; Collins, D. R.; O'Neill, D.; Murphy, S. J.X.; Lim, S. J.; Murphy, R. P.; McCabe, D. J.H.

In: Journal of the Neurological Sciences, Vol. 375, 15.04.2017, p. 404-410.

Research output: Contribution to journalArticle

Tobin, W, Kinsella, JA, Kavanagh, GF, O'Donnell, JS, McGrath, RT, Tierney, S, Egan, B, Feeley, TM, Coughlan, T, Collins, DR, O'Neill, D, Murphy, SJX, Lim, SJ, Murphy, RP & McCabe, DJH 2017, 'Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes', Journal of the Neurological Sciences, vol. 375, pp. 404-410. https://doi.org/10.1016/j.jns.2017.02.045
Tobin, William ; Kinsella, J. A. ; Kavanagh, G. F. ; O'Donnell, J. S. ; McGrath, R. T. ; Tierney, S. ; Egan, B. ; Feeley, T. M. ; Coughlan, T. ; Collins, D. R. ; O'Neill, D. ; Murphy, S. J.X. ; Lim, S. J. ; Murphy, R. P. ; McCabe, D. J.H. / Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes. In: Journal of the Neurological Sciences. 2017 ; Vol. 375. pp. 404-410.
@article{44410eff85034f8491c4ad6c129d00c7,
title = "Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes",
abstract = "Introduction Von Willebrand factor propeptide (VWF:Ag II) is proposed to be a more sensitive marker of acute endothelial activation than von Willebrand factor antigen (VWF:Ag). Simultaneous data on VWF:Ag and VWF:Ag II profiles are very limited following TIA and ischaemic stroke. Methods In this prospective, observational, case-control study, plasma VWF:Ag and VWF:Ag II levels were quantified in 164 patients ≤ 4 weeks of TIA or ischaemic stroke (baseline), and then ≥ 14 days (14d) and ≥ 90 days (90d) later, and compared with those from 27 healthy controls. TIA and stroke subtyping was performed according to the TOAST classification. The relationship between VWF:Ag and VWF:Ag II levels and platelet activation status was assessed. Results ‘Unadjusted’ VWF:Ag and VWF:Ag II levels were higher in patients at baseline, 14d and 90d than in controls (p ≤ 0.03). VWF:Ag levels remained higher in patients than controls at baseline (p ≤ 0.03), but not at 14d or 90d after controlling for differences in age or hypertension, and were higher in patients at baseline and 90d after controlling for smoking status (p ≤ 0.04). ‘Adjusted’ VWF:Ag II levels were not higher in patients than controls after controlling for age, hypertension or smoking (p ≥ 0.1). Patients with symptomatic carotid stenosis (N = 46) had higher VWF:Ag and VWF:Ag II levels than controls at all time-points (p ≤ 0.002). There was no significant correlation between platelet activation status and VWF:Ag or VWF:Ag II levels. Conclusions VWF:Ag and VWF:Ag II levels are increased in an overall TIA and ischaemic stroke population, especially in patients with recently symptomatic carotid stenosis. VWF:Ag II was not superior to VWF:Ag at detecting acute endothelial activation in this cohort and might reflect timing of blood sampling in our study.",
keywords = "Case-control, Stroke, TIA, Von Willebrand factor, Von Willebrand factor propeptide",
author = "William Tobin and Kinsella, {J. A.} and Kavanagh, {G. F.} and O'Donnell, {J. S.} and McGrath, {R. T.} and S. Tierney and B. Egan and Feeley, {T. M.} and T. Coughlan and Collins, {D. R.} and D. O'Neill and Murphy, {S. J.X.} and Lim, {S. J.} and Murphy, {R. P.} and McCabe, {D. J.H.}",
year = "2017",
month = "4",
day = "15",
doi = "10.1016/j.jns.2017.02.045",
language = "English (US)",
volume = "375",
pages = "404--410",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes

AU - Tobin, William

AU - Kinsella, J. A.

AU - Kavanagh, G. F.

AU - O'Donnell, J. S.

AU - McGrath, R. T.

AU - Tierney, S.

AU - Egan, B.

AU - Feeley, T. M.

AU - Coughlan, T.

AU - Collins, D. R.

AU - O'Neill, D.

AU - Murphy, S. J.X.

AU - Lim, S. J.

AU - Murphy, R. P.

AU - McCabe, D. J.H.

PY - 2017/4/15

Y1 - 2017/4/15

N2 - Introduction Von Willebrand factor propeptide (VWF:Ag II) is proposed to be a more sensitive marker of acute endothelial activation than von Willebrand factor antigen (VWF:Ag). Simultaneous data on VWF:Ag and VWF:Ag II profiles are very limited following TIA and ischaemic stroke. Methods In this prospective, observational, case-control study, plasma VWF:Ag and VWF:Ag II levels were quantified in 164 patients ≤ 4 weeks of TIA or ischaemic stroke (baseline), and then ≥ 14 days (14d) and ≥ 90 days (90d) later, and compared with those from 27 healthy controls. TIA and stroke subtyping was performed according to the TOAST classification. The relationship between VWF:Ag and VWF:Ag II levels and platelet activation status was assessed. Results ‘Unadjusted’ VWF:Ag and VWF:Ag II levels were higher in patients at baseline, 14d and 90d than in controls (p ≤ 0.03). VWF:Ag levels remained higher in patients than controls at baseline (p ≤ 0.03), but not at 14d or 90d after controlling for differences in age or hypertension, and were higher in patients at baseline and 90d after controlling for smoking status (p ≤ 0.04). ‘Adjusted’ VWF:Ag II levels were not higher in patients than controls after controlling for age, hypertension or smoking (p ≥ 0.1). Patients with symptomatic carotid stenosis (N = 46) had higher VWF:Ag and VWF:Ag II levels than controls at all time-points (p ≤ 0.002). There was no significant correlation between platelet activation status and VWF:Ag or VWF:Ag II levels. Conclusions VWF:Ag and VWF:Ag II levels are increased in an overall TIA and ischaemic stroke population, especially in patients with recently symptomatic carotid stenosis. VWF:Ag II was not superior to VWF:Ag at detecting acute endothelial activation in this cohort and might reflect timing of blood sampling in our study.

AB - Introduction Von Willebrand factor propeptide (VWF:Ag II) is proposed to be a more sensitive marker of acute endothelial activation than von Willebrand factor antigen (VWF:Ag). Simultaneous data on VWF:Ag and VWF:Ag II profiles are very limited following TIA and ischaemic stroke. Methods In this prospective, observational, case-control study, plasma VWF:Ag and VWF:Ag II levels were quantified in 164 patients ≤ 4 weeks of TIA or ischaemic stroke (baseline), and then ≥ 14 days (14d) and ≥ 90 days (90d) later, and compared with those from 27 healthy controls. TIA and stroke subtyping was performed according to the TOAST classification. The relationship between VWF:Ag and VWF:Ag II levels and platelet activation status was assessed. Results ‘Unadjusted’ VWF:Ag and VWF:Ag II levels were higher in patients at baseline, 14d and 90d than in controls (p ≤ 0.03). VWF:Ag levels remained higher in patients than controls at baseline (p ≤ 0.03), but not at 14d or 90d after controlling for differences in age or hypertension, and were higher in patients at baseline and 90d after controlling for smoking status (p ≤ 0.04). ‘Adjusted’ VWF:Ag II levels were not higher in patients than controls after controlling for age, hypertension or smoking (p ≥ 0.1). Patients with symptomatic carotid stenosis (N = 46) had higher VWF:Ag and VWF:Ag II levels than controls at all time-points (p ≤ 0.002). There was no significant correlation between platelet activation status and VWF:Ag or VWF:Ag II levels. Conclusions VWF:Ag and VWF:Ag II levels are increased in an overall TIA and ischaemic stroke population, especially in patients with recently symptomatic carotid stenosis. VWF:Ag II was not superior to VWF:Ag at detecting acute endothelial activation in this cohort and might reflect timing of blood sampling in our study.

KW - Case-control

KW - Stroke

KW - TIA

KW - Von Willebrand factor

KW - Von Willebrand factor propeptide

UR - http://www.scopus.com/inward/record.url?scp=85013938209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013938209&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2017.02.045

DO - 10.1016/j.jns.2017.02.045

M3 - Article

VL - 375

SP - 404

EP - 410

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

ER -